•Professor of Medicine & Interventional Cardiologist: #Aging @ClevelandClinic •Dean’s Scholar: #Finance #Biotech @NYUStern
•Mesopotamian
🥸 1️⃣ Inflammation and cardiovascular disease frames risk beyond cholesterol; residual inflammatory risk by hsCRP often persists despite statins, so a patient with LDL at goal but hsCRP 3–5 mg/L still faces higher event rates and needs a plan that targets inflammation directly.
🥸1️⃣ For decades, aspirin has been the default long-term therapy for preventing recurrent cardiovascular events in patients with established coronary artery disease. It has been embedded in clinical guidelines based largely on historical data.
🥸1️⃣ GLP-1 receptor agonists (GLP-1RAs) were originally developed for diabetes and weight loss. SELECT expanded their role, showing semaglutide reduces cardiovascular events in non-diabetic patients with obesity and established cardiovascular disease.
🥸1️⃣ The POTCAST trial tested if raising potassium to the high-normal range (4.5–5.0 mmol/L) reduces malignant arrhythmias, hospitalizations, or death in patients with cardiovascular disease and an implanted defibrillator.
🥸1️⃣ The REBOOT trial evaluated beta-blockers after MI in patients with LVEF >40%. The trial tested whether routine beta-blockers reduce death, reinfarction, or heart failure hospitalization.
🥸 1️⃣ The BETAMI–DANBLOCK trial, a large, pragmatic randomized trial from Denmark and Norway, asked whether long-term beta-blockers reduce death or cardiovascular events in post-MI patients with preserved or mildly reduced LVEF but no heart failure.
🥸1️⃣ ASPREE was a large randomized trial designed to evaluate whether daily low-dose aspirin prevents cardiovascular events in initially healthy older adults.
🥸1️⃣ Acute coronary syndromes remain a leading cause of global mortality, with one out of three deaths attributed to atherosclerosis and its acute or chronic complications.
🥸1️⃣ This Danish nationwide cohort study examined the 10-year risk of first-time infective endocarditis (IE) in patients after mitral valve (MV) replacement or repair, compared to those at moderate risk of IE, using high-quality registry data from 2000–2020.
🥸1️⃣ Alcohol use and cardiovascular disease (CVD) have a complicated and often debated relationship; this AHA statement reviews decades of research on coronary artery disease (CAD), stroke, heart failure (HF), arrhythmias, and cardiomyopathy.
🥸 1️⃣ SURMOUNT-5 directly compares tirzepatide and semaglutide for obesity in adults without diabetes. First head-to-head randomized trial of these two GLP-1–based agents. Published @NEJM, May 2025. 
🥸 1️⃣ Healthy ageing in cardiovascular disease matters because by 2050, adults 65+ will represent over 20% of the U.S. and nearly 30% of Europe's population, dramatically shifting healthcare needs.
🥸1️⃣ In cancer-associated VTE, extended anticoagulation is common—but the dose remains uncertain. The API-CAT trial tested reduced-dose vs. full-dose apixaban after 6 months of initial therapy.
🥸1️⃣ Lifetime cardiovascular risk increases with the number of classic risk factors you carry at age 50. The Global Cardiovascular Risk Consortium analyzed over 2 million people to estimate how much risk factors shorten life and healthspan.
🥸1️⃣ Elevated concentrations of lipoprotein(a) are a strong, independent risk factor for cardiovascular disease. Lepodisiran, a long-acting small interfering RNA, targets hepatic production of lipoprotein(a).
🥸1️⃣ In patients with suspected ACS, a 12-lead ECG should be acquired and interpreted within 10 minutes of first medical contact to identify patients with STEMI.
🥸 1️⃣ Hunger is an ancient survival mechanism that evolved to keep humans alive in times of food scarcity.
🥸 1️⃣ Abelacimab significantly reduced bleeding in atrial fibrillation patients compared to rivaroxaban, as reported in the AZALEA–TIMI 71 trial.
🥸 1/ ATTR-CM is a progressive, fatal disease. It occurs due to misfolded transthyretin proteins depositing in the heart muscle, causing infiltrative cardiomyopathy. Vutrisiran, an RNA interference agent, offers new therapy by targeting the production of hepatic transthyretin.
🥸 1️⃣ Atrial fibrillation (AF) affects ~10.55 million US adults. It increases the risk of stroke, heart failure (HF), myocardial infarction, chronic kidney disease, dementia, and death. 
🥸 1️⃣ Obesity drives heart failure with preserved ejection fraction (HFpEF) through systemic inflammation and visceral adiposity. Tirzepatide, a dual GIP and GLP-1 receptor agonist, offers weight loss and potential cardiovascular benefits.